Clinical trials: Thalidomide
Multiple Myeloma
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
This study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects
- Trial name
- NCT03004287
- Testing
- Carfilzomib, Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Arkansas
Amyloidosis
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
This study evaluates the safety and efficacy of carfilzomib used in combination with thalidomide and dexamethasone in patients with relapsed AL amyloidosis.
- Trial name
- CATALYST (NCT02545907)
- Testing
- Carfilzomib, Thalidomide, Dexamethasone
- Where
- 14 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- University College, London
Alzheimer's Disease
Thalidomide for Patients With Mild to Moderate Alzheimer's Disease
This is a 24-week, randomized, double-blind, placebo-controlled study of the effect of thalidomide and placebo on CSF (cerebral spinal fluid) and plasma biomarkers in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT01094340
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Banner Health
Crohn's Disease
Thalidomide in Treating Crohn's Disease
Crohn's disease (CD) is a chronic gastrointestinal inflammatory disease characterized by relapse and progression. The incidence and prevalence of IBD are increasing in different regions around the world, indicating its emergence…
- Trial name
- NCT02501291
- Testing
- Thalidomide
- Where
- China
- Volunteers
- 47 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Haemodialysis, Uremic Pruritus
A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus
The purpose of this study is to evaluate the safety and efficacy of thalidomide in the treatment of refractory uremic pruritus in maintenance hemodialysis patients.
- Conditions
- Haemodialysis, Uremic Pruritus, Thalidomide
- Trial name
- NCT05525234
- Testing
- Thalidomide
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
Multiple Myeloma
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
The primary purpose of this study is to determine the overall response rate (ORR) during induction therapy with the combination of ixazomib, thalidomide and low-dose dexamethasone in specific time points.
- Trial name
- IDEALL (NCT03608501)
- Testing
- Ixazomib, Thalidomide, Dexamethasone
- Where
- 6 sites in Brazil
- Sponsor
- Takeda
Multiple Myeloma
Study of Combination PS-341 and Thalidomide in Multiple Myeloma
The purpose of this study is to assess the toxicity of PS-341 combined with one of four doses of thalidomide in patients with refractory multiple myeloma, and to find the most appropriate doses of PS-341 and thalidomide in the…
- Trial name
- NCT00083460
- Testing
- PS-341, Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- University of Arkansas
Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival.
- Trial name
- NCT02085655
- Testing
- pegaspargase, Gemcitabine, Oxaliplatin
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Huiqiang Huang
Chronic Myeloproliferative Disorders, Leukemia
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00274820
- Testing
- ascorbic acid, arsenic trioxide, dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Case Comprehensive Cancer Center
Hepatocellular Carcinoma
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
Chemoembolization (TACE) is used in the majority of advanced hepatocellular carcinomas. Randomized clinical trials indicated that TACE improves overall survival in patients with good liver function (Child-pugh A or B).
- Trial name
- NCT00921531
- Testing
- Thalidomide, TACE
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Brain and Central Nervous System Tumors, Glioblastoma Multiforme
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112502
- Testing
- Celecoxib, Isotretinoin, Temozolomide
- Where
- 12 sites in United States
- Volunteers
- 178 people
- Sponsor
- M.D. Anderson Cancer Center
Thalassemia
Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia
The aim of this study is to determine the safety and therapeutic effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on beta thalassemia patients.
- Trial name
- NCT07673302
- Testing
- Thalidomide, Hydroxy Urea
- Where
- Pakistan
- Volunteers
- 240 people
- Sponsor
- Riphah International University
Multiple Myeloma
Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients
The purpose of this study is to evaluate the safety and the efficacy of the association of Melphalan/Prednisone/Thalidomide/VELCADE (MPTV) as salvage treatment in advanced and refractory myeloma patients.
- Trial name
- NCT00358020
- Testing
- THALIDOMIDE, BORTEZOMIB
- Where
- 7 sites in Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy
Intraocular Melanoma, Melanoma (Skin)
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00238329
- Testing
- PEG-interferon alfa-2b, thalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
Thalidomide may stop the growth of soft tissue sarcoma by stopping blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7
- Trial name
- NCT00089544
- Testing
- Dacarbazine, Doxorubicin Hydrochloride, Filgrastim
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Newly Diagnosed Multiple Myeloma
Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma
This is an observational, multi-center, non-interventional study, which is designed to evaluate the safety and efficacy of daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone (D-VTD) Regimens in NDMM…
- Trial name
- NCT05561049
- Testing
- Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Brain and Central Nervous System Tumors
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00014443
- Testing
- thalidomide, topotecan hydrochloride
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Rush University Medical Center
Multiple Myeloma
A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)
In this study, researchers want to find out if using the VTD regimen, along with higher doses melphalan, in subjects who have relapsed or progressed after previous transplant(s), can be given safely to subjects who have failed…
- Trial name
- NCT00577668
- Testing
- Melphalan, Velcade, Thalidomide, Dexamethasone
- Where
- United States
- Sponsor
- University of Arkansas
Multiple Myeloma, Newly Diagnosed Multiple Myeloma
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
This research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the combination of daratumumab, lenalidomide, bortezomib, dexamethasone for…
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
- Trial name
- ELDORADO (NCT07247097)
- Testing
- Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Massachusetts General Hospital
Head and Neck Cancer
Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase II trial to study the effectiveness of thalidomide in treating patients with recurrent or metastatic head and neck cancer. Thalidomide may stop the growth of head and neck cancer by stopping blood flow to the tumor.
- Trial name
- NCT00003850
- Testing
- thalidomide
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)